Clinical Trial Detail

NCT ID NCT03515538
Title Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors EpicentRx, Inc.
Indications

oropharynx cancer

oral squamous cell carcinoma

Therapies

Cisplatin + RRx-001

RRx-001

Age Groups: adult senior

No variant requirements are available.